Literature DB >> 32820423

Prototype device for endoventricular beta-emitting radiotracer detection and molecularly-guided intervention.

John C Stendahl1, Zhao Liu2, Nabil E Boutagy1, Eliahoo Nataneli3, Farhad Daghighian3, Albert J Sinusas4,5,6.   

Abstract

BACKGROUND: We have set out to develop a catheter-based theranostic system that: (a) identifies diseased and at-risk myocardium via endocardial detection of systemically delivered β-emitting radiotracers and (b) utilizes molecular signals to guide delivery of therapeutics to appropriate tissue via direct intramyocardial injection.
METHODS: Our prototype device consists of a miniature β-radiation detector contained within the tip of a flexible intravascular catheter. The catheter can be adapted to incorporate an injection port and retractable needle for therapeutic delivery. The performance of the β-detection catheter was assessed in vitro with various β-emitting radionuclides and ex vivo in hearts of pigs following systemic injection of 18F-fluorodeoxyglucose (18F-FDG) at 1-week post-myocardial infarction. Regional catheter-based endocardial measurements of 18F activity were compared to regional tissue activity from PET/CT images and gamma counting.
RESULTS: The β-detection catheter demonstrated sensitive in vitro detection of β-radiation from 22Na (β+), 18F (β+), and 204Tl (β-), with minimal sensitivity to γ-radiation. For 18F, the catheter demonstrated a sensitivity of 4067 counts/s/μCi in contact and a spatial resolution of 1.1 mm FWHM. Ex vivo measurements of endocardial 18F activity with the β-detection catheter in the chronic pig infarct model demonstrated good qualitative and quantitative correlation with regional tissue activity from PET/CT images and gamma counting.
CONCLUSION: The prototype β-detection catheter demonstrates sensitive and selective detection of β- and β+ emissions over a wide range of energies and enables high-fidelity ex vivo characterization of endocardial activity from systemically delivered 18F-FDG.
© 2020. American Society of Nuclear Cardiology.

Entities:  

Keywords:  Image guided application; PET; instrumentation; molecular imaging; myocardial ischemia and infarction

Mesh:

Substances:

Year:  2020        PMID: 32820423      PMCID: PMC7895860          DOI: 10.1007/s12350-020-02317-8

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  48 in total

1.  Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fibroblasts.

Authors:  Wei Chen; Amit Saxena; Na Li; Jinyu Sun; Amit Gupta; Dong-Wook Lee; Qi Tian; Marcin Dobaczewski; Nikolaos G Frangogiannis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-20       Impact factor: 8.311

2.  PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI.

Authors:  Arshed A Quyyumi; Alejandro Vasquez; Dean J Kereiakes; Marc Klapholz; Gary L Schaer; Ahmed Abdel-Latif; Stephen Frohwein; Timothy D Henry; Richard A Schatz; Nabil Dib; Catalin Toma; Charles J Davidson; Gregory W Barsness; David M Shavelle; Martin Cohen; Joseph Poole; Thomas Moss; Pamela Hyde; Anna Maria Kanakaraj; Vitaly Druker; Amy Chung; Candice Junge; Robert A Preti; Robin L Smith; David J Mazzo; Andrew Pecora; Douglas W Losordo
Journal:  Circ Res       Date:  2016-11-07       Impact factor: 17.367

3.  Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin.

Authors:  Moustapha E Moustapha; Gary J Ehrhardt; Charles J Smith; Lawrence P Szajek; William C Eckelman; Silvia S Jurisson
Journal:  Nucl Med Biol       Date:  2006-01       Impact factor: 2.408

Review 4.  Diagnostic and prognostic value of 3D NOGA mapping in ischemic heart disease.

Authors:  Mariann Gyöngyösi; Nabil Dib
Journal:  Nat Rev Cardiol       Date:  2011-05-17       Impact factor: 32.419

5.  Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction.

Authors:  Zakir H Sahul; Rupak Mukherjee; James Song; Jarod McAteer; Robert E Stroud; Donald P Dione; Lawrence Staib; Xenophon Papademetris; Lawrence W Dobrucki; James S Duncan; Francis G Spinale; Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2011-04-19       Impact factor: 7.792

6.  Optimized delivery system achieves enhanced endomyocardial stem cell retention.

Authors:  Atta Behfar; Jean-Pierre Latere; Jozef Bartunek; Christian Homsy; Dorothee Daro; Ruben J Crespo-Diaz; Paul G Stalboerger; Valerie Steenwinckel; Aymeric Seron; Margaret M Redfield; Andre Terzic
Journal:  Circ Cardiovasc Interv       Date:  2013-12-10       Impact factor: 6.546

7.  Feasibility and kinetic characteristics of (68)Ga-NOTA-RGD PET for in vivo atherosclerosis imaging.

Authors:  Jin Chul Paeng; Yun-Sang Lee; Jae Sung Lee; Jae Min Jeong; Ki-Bong Kim; June-Key Chung; Dong Soo Lee
Journal:  Ann Nucl Med       Date:  2013-08-06       Impact factor: 2.668

8.  Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction.

Authors:  Sunil V Rao; Uwe Zeymer; Pamela S Douglas; Hussein Al-Khalidi; Jennifer A White; Jingyu Liu; Howard Levy; Victor Guetta; C Michael Gibson; Jean-Francois Tanguay; Paul Vermeersch; Jérôme Roncalli; Jaroslaw D Kasprzak; Timothy D Henry; Norbert Frey; Oscar Kracoff; Jay H Traverse; Derek P Chew; Jose Lopez-Sendon; Reinilde Heyrman; Mitchell W Krucoff
Journal:  J Am Coll Cardiol       Date:  2016-08-16       Impact factor: 24.094

Review 9.  Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives.

Authors:  Nicolas Lepareur; Franck Lacœuille; Christelle Bouvry; François Hindré; Emmanuel Garcion; Michel Chérel; Nicolas Noiret; Etienne Garin; F F Russ Knapp
Journal:  Front Med (Lausanne)       Date:  2019-06-14

10.  Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.

Authors:  Eugene S Chung; Leslie Miller; Amit N Patel; Russell David Anderson; Farrell O Mendelsohn; Jay Traverse; Kevin H Silver; Julia Shin; Gregory Ewald; Mary Jane Farr; Saif Anwaruddin; Francis Plat; Scott J Fisher; Alexander T AuWerter; Joseph M Pastore; Rahul Aras; Marc S Penn
Journal:  Eur Heart J       Date:  2015-06-07       Impact factor: 29.983

View more
  2 in total

Review 1.  Nuclear Cardiac Imaging in the Interventional Suite.

Authors:  Zachary Pickell; Albert J Sinusas
Journal:  Curr Cardiol Rep       Date:  2022-01-13       Impact factor: 2.931

2.  Fantastic voyage: Catheter-based quantification of tracer distribution on a miniature scale.

Authors:  James T Thackeray
Journal:  J Nucl Cardiol       Date:  2020-10-06       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.